1-3 of 3
David A. Scheinberg
Close
Sort by
Journal Articles

Therapeutic targeting of PRAME with mTCR CAR T cells in acute myeloid leukemia

Danielle C. Kirkey, Anisha M. Loeb, Sommer Castro, Cyd Nourigat McKay, LaKeisha Perkins, Laura Pardo, Amanda R. Leonti, Thao T. Tang, Michael R. Loken, Lisa Eidenschink Brodersen, Keith R. Loeb, David A. Scheinberg, Quy Le, Soheil Meshinchi
Journal: Blood Advances
Blood Adv (2023) 7 (7): 1178–1189.
https://doi.org/10.1182/bloodadvances.2022008304
Published: 2023
Includes: Supplemental data
Journal Articles

Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment

Christopher M. Bourne, Sung Soo Mun, Tao Dao, Zita E. H. Aretz, Zaki Molvi, Ron S. Gejman, Andrew Daman, Katsuyoshi Takata, Christian Steidl, Martin G. Klatt, David A. Scheinberg
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4107–4121.
https://doi.org/10.1182/bloodadvances.2021006069
Published: 2022
Includes: Supplemental data
Journal Articles

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia

Clinical Trials & Observations
Peter G. Maslak, Tao Dao, Yvette Bernal, Suzanne M. Chanel, Rong Zhang, Mark Frattini, Todd Rosenblat, Joseph G. Jurcic, Renier J. Brentjens, Maria E. Arcila, Raajit Rampal, Jae H. Park, Dan Douer, Laura Katz, Nicholas Sarlis, Martin S. Tallman, David A. Scheinberg
Journal: Blood Advances
Blood Adv (2018) 2 (3): 224–234.
https://doi.org/10.1182/bloodadvances.2017014175
Published: 2018
Includes: Supplemental data